Cargando…
Institutional Experience of Using Andexanet Alfa
Given their ease of use, safety, and efficacy, direct-acting oral anticoagulants (DOACs) are nowadays widely used in patients with atrial fibrillation or venous thromboembolism, with or without an association with malignancy. Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy...
Autores principales: | Khadka, Sushmita, Kasireddy, Vineela, Dhakal, Pravash |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425824/ https://www.ncbi.nlm.nih.gov/pubmed/32802609 http://dx.doi.org/10.7759/cureus.9173 |
Ejemplares similares
-
Evolving treatment modalities for immune thrombocytopenia in adults
por: Khadka, Sushmita, et al.
Publicado: (2021) -
Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018) -
Successful use of an antithrombin for heparin resistance with andexanet alfa
por: Honda, Jun, et al.
Publicado: (2023) -
Correction to: Andexanet Alfa: First Global Approval
por: Heo, Young-A
Publicado: (2018) -
Andexanet alfa — Recommendations for clinical use. Multidisciplinary experts’ standpoint
por: Kubica, Jacek, et al.
Publicado: (2023)